The latest news on life science tools and technology in genetics, genomics, and molecular diagnostics.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene.
